It seems like everywhere we turn, someone’s talking about glucagon-like peptide-1 (GLP-1) receptor agonist medications — and for good reason. You more than likely already know the names: semaglutide (Ozempic, Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound).
Some online clinics and medical spas are now advertising GLP-1s as longevity treatments, which begs the question, could GLP-1s help people live longer, healthier lives? The honest answer: We don’t know yet. Here’s what we do know about what the research says.
“If we’re asking if GLP-1s make you live longer, like more number of years, we have no data and no science to support that,” says Rekha Kumar, MD, an endocrinologist and obesity medicine expert at Iris Cantor Women's Health Center in New York City. “If the question is, could this class of medicine keep you healthier for longer within your lifespan, the answer is the science is moving in that direction to support that.”
Researchers are actively studying how GLP-1 drugs impact key biological processes — including
chronic inflammation, cellular energy, heart health, and
brain function — all of which are major factors that determine both how long you live, which is known as lifespan, and how healthy you are during those years, which is referred to as
healthspan.
“In cellular studies, we see reduced chronic inflammation, improved mitochondrial function [cell energy], better vascular function [blood flow], reduced oxidative stress,” says Dr. Kumar. “All of these things are cellular evidence that GLP-1s can be helpful.”
According to Reshmi Srinath, MD, director of the Mount Sinai Weight and Metabolism Management Program in New York City, research is taking place to establish if GLP-1s may have even more impact on factors related to aging.
“Drug companies are currently investigating the role of GLP-1s in aging and immune function, and they’re being studied in autoimmune disease and neurological conditions,” she says.
Inflammation and Aging
One reason GLP-1s are linked to longevity is their effect on oxidative stress, which is an imbalance of harmful molecules called
free radicals that damage cells and trigger chronic inflammation.
Sometimes called “inflammaging,” chronic inflammation is a major factor in age-related decline.
“GLP-1s reduce inflammation in the body,” says Kumar. “That type of inflammation not only leads to cardiovascular disease, but also to cancers, neurodegenerative disease (Alzheimer’s disease and Parkinson’s), and arthritis.”
Heart and Organ Protection
Protecting the heart — the organ most associated with early death — is another area of scientific interest.
“The SELECT trial found that people taking GLP-1s had a lower risk of heart attack, stroke, and death, even when they didn’t lose much weight,” says Kumar. “This shows the benefits go beyond just weight or blood sugar.”
Beyond the heart, GLP-1s may help protect the
kidneys and liver from damage caused by
metabolic disease, a group of conditions that include
hypertension, and abdominal obesity.
Cancer and Metabolic Health
Researchers are also exploring GLP-1s for the prevention of obesity-related cancers, which make up nearly 40 percent of U.S. cancer diagnoses. There are 13 types of cancers that are linked to obesity, including
breast,
colon and rectal,
liver, and
pancreatic cancer.
“For patients who don’t need to lose weight or treat diabetes, there’s growing interest in using GLPs to prevent chronic conditions like cancer,” says Kumar. “The benefits appear to come from both direct effects and improvements in blood sugar and body fat.”
Cellular Aging
Cellular aging is the gradual decline in a cell’s ability to function properly. Research indicates that GLP-1s may improve the function of mitochondria — structures within cells that produce almost all the energy your body needs — and reduce cellular stress, says Kumar.
“It could be hypothesized or extrapolated that this would also have a benefit on cellular aging,” she says.
Brain Health and Neuroprotection
Science is suggesting that GLP-1s may have a protective effect on the brain, too. Early studies suggest semaglutide may lower
Alzheimer’s disease risk in people with type 2 diabetes by reducing inflammation, improving blood sugar, and protecting brain cells. However, research in otherwise healthy adults is still limited, and GLP-1s are not yet approved for preventing
dementia.
Kumar describes a patient with a strong family history of Alzheimer’s who asked to try a GLP-1 for dementia prevention. “She was very fit and optimized her lifestyle, diet, sleep, and stress management,” she says. “We tried it, but she didn’t tolerate it — she became nauseous and lost weight she didn’t need.”
In this case, the risk outweighed the potential benefits, raising the question of whether GLP-1s offer the same longevity advantages for people without a medical indication for their use.
Despite early buzz about possible benefits, GLP-1 medications are not FDA-approved for longevity or preventing age-related disease. Yet doctors can prescribe them off-label for patients.
Still, there are important considerations
. Off-label use is rarely covered by insurance, which can lead to high out-of-pocket costs, and has pushed some people toward
compounded GLP-1 products, which are medications made by a pharmacy to create customized doses. Unlike brand-name GLP-1s, these products are not FDA-approved, so safety, purity, and effectiveness may vary.
Kumar urges anyone thinking about GLP-1s for longevity or healthspan to sit down with their doctor, not fill out a quick form online.
“I don’t think patients always know what they’re asking when they say they want a GLP-1 for longevity,” he says. “Are they hoping to live longer? Reduce inflammation? I don't think any of these conversations can really move forward without talking about lifestyle risk factor modification.”
Many of the compounding pharmacies marketing GLP1s for longevity suggest
microdosing, or taking very small doses of the medication. The idea is that tiny doses might provide benefits while lowering the risk of side effects, while potentially limiting the amount of weight loss for people who aren’t seriously overweight.
While microdosing is not officially recommended by drugmakers and lacks large-scale clinical trial evidence, Kumar says, “It does make sense. … If a smaller dose works for someone, if they feel better and their inflammation improves, then they don’t necessarily need a higher dose.”
Yet microdosing should only be done with medical guidance. “I work with patients individually to adjust medication doses based on their progress and weight loss and as they reach their goal,” says Dr. Srinath.
There haven’t been enough studies to make that determination yet. Long-term data is limited because these drugs are relatively new.
“These drugs have tremendous benefit, but more ongoing studies are needed outside of patients with diabetes, obesity, and metabolic disease before we can apply safely,” says Srinath.
Like any medication, GLP-1s can cause side effects, including
acid reflux, constipation, fatigue, headaches, indigestion, mild nausea, and vomiting. These symptoms often lessen as your body adjusts or your dose is decreased. Some studies show side effects may be more pronounced in
older adults, increasing the likelihood they’ll stop taking it.
People aged 65 and older may also be more susceptible to
muscle mass loss, which is concerning since age naturally reduces bone and muscle strength, increasing the risk of falls and fractures.
GLP-1 medications can benefit many people, but they aren’t the right choice for everyone. Your doctor may advise against them if you:
- Have a personal or family history of certain thyroid cancers, including medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2)
- Are pregnant, breastfeeding, or planning a pregnancy
- Have had pancreatitis
- Have serious stomach or gastrointestinal problems
- Have a history of an eating disorder or disordered eating
- Drink a lot of alcohol
- Are medically frail or have very low muscle mass
- Aren’t able to make supportive lifestyle changes, like adjusting eating patterns or increasing activity
Kumar stresses the importance of working closely with your doctor to not only monitor risk factors and side effects but to make sure you are setting foundational health habits. “There’s no real benefit to adding a GLP-1 for longevity if you can still modify lifestyle risk factors. It’s going to be less effective,” she says. “Once someone has done all the right things for nutrition, fitness, sleep, stress management, and frailty prevention, then having a conversation about adding a pharmacologic option for longevity or optimization becomes appropriate.”
- GLP-1 medications, like semaglutide and tirzepatide, were originally developed for diabetes, but researchers are now exploring if they may extend lifespan and help people maintain good health for a longer period of time.
- Early evidence suggests GLP-1s may reduce chronic inflammation and improve cellular function, supporting heart, liver, kidney, and brain health, and potentially lowering risk for obesity-related cancers. However, there is no current proof they extend lifespan.
- GLP-1s are not currently approved for longevity but can be prescribed off-label, including for microdosing. Experts emphasize that these drugs should complement — not replace — foundational lifestyle habits like nutrition, exercise, sleep, and stress management.
Find everything you need to know about GLP-1 drugs—all in one place.
Rachel Green
Rachel Davis
Derek Schulz
Sophia Martinez
Dr. Amara Okafor